A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis (Q33983913)

30 July 2017

title

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

Motasim Badri

0 references

Jeannine M Heckmann

0 references

Amanullah Rawoot

1 reference

30 July 2017

Kathleen Bateman

series ordinal

1 reference

30 July 2017

Rudi Renison

series ordinal

1 reference

30 July 2017

publication date

5 August 2011

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Practice parameters and technology assessments: what they are, what they are not, and why you should care

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

The MGTX experience: challenges in planning and executing an international, multicenter clinical trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

When the patient fails to respond to treatment: myasthenia gravis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Immunosuppressive agents for myasthenia gravis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Optimal use of methotrexate: the advantages of tight control

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Clinical evaluation and management of myasthenia gravis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Treatment of autoimmune myasthenia gravis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Thymoma in patients with MG: characteristics and long-term outcome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Reliability testing of the quantitative myasthenia gravis score

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Lifetime course of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-97

Incidence of seropositive myasthenia gravis in Cape Town and South Africa.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170595

Therapies for disorders of the neuromuscular junction

29 October 2018

1 reference

12 December 2020

The treatment of severe myasthenia gravis with immunosuppressive agents

1 reference

12 December 2020

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

1 reference

12 December 2020

Methotrexate--the relationship between dose and clinical effect

1 reference

12 December 2020

Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis

1 reference

12 December 2020

Myasthenia gravis activities of daily living profile

1 reference

12 December 2020

Myasthenia gravis in South Africans: racial differences in clinical manifestations

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-11-97

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference